ReviewPharmaceutics2022
Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Concurrent Mold, Mycobacterial, and Viral Infections in a Hematopoietic Stem Cell Transplant Recipient Undergoing Lung Transplantation for Graft-Versus-Host Disease.Current oncology (Toronto, Ont.) · 2026Article
- Condensation of fluconazole and zinc undecylanate particles using low-pressure RF plasma: a novel drug combination approach.BMC pharmacology & toxicology · 2025Article
- Pulmonary Infiltrates in a Non-Cystic Fibrosis Bronchiectasis Patient: A Case Report.Journal of clinical medicine · 2025Article
- Voriconazole-Loaded Nanohydrogels Towards Optimized Antifungal Therapy for Cystic Fibrosis Patients.Pharmaceutics · 2025Article
- Role of liposomal amphotericin B in intensive care unit: an expert opinion paper.Journal of anesthesia, analgesia and critical care · 2025Review
- Graphene nanomaterials: A new frontier in preventing respiratory fungal infections.Current medical mycology · 2025Review
- A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations.Journal of pharmaceutical policy and practice · 2025Article
- Diverse antifungal potency of terbinafine as a therapeutic agent against Exophiala dermatitidis in vitro.Scientific reports · 2024Article
- Fungal lung disease.The European respiratory journal · 2024Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024Review
- Nebuliser therapy in critical care: The past, present and future.Journal of the Intensive Care Society · 2024Review
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients.Pathogens (Basel, Switzerland) · 2023Review
- Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges.Journal of fungi (Basel, Switzerland) · 2023Review
- Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.Journal of fungi (Basel, Switzerland) · 2023Article
- Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?Pharmaceutics · 2022Review
- InvasiveDiagnostics (Basel, Switzerland) · 2022Review
- Case report: AcuteFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary mold infections are life-threatening diseases with high morbi-mortalities. Treatment is based on systemic antifungal agents belonging to the families of polyenes (amphotericin B) and triazoles. Despite this treatment, mortality remains high and the doses of systemic antifungals cannot be increased as they often lead to toxicity. The pulmonary aerosolization of antifungal agents can theoretically increase their concentration at the infectious site, which could improve their efficacy while limiting their systemic exposure and toxicity. However, clinical experience is poor and thus inhaled agent utilization remains unclear in term of indications, drugs, and devices. This comprehensive literature review aims to describe the pharmacokinetic behavior and the efficacy of inhaled antifungal drugs as prophylaxes and curative treatments both in animal models and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.